JP6300042B2 - 癌の処置に使用するための化合物の製造方法 - Google Patents

癌の処置に使用するための化合物の製造方法 Download PDF

Info

Publication number
JP6300042B2
JP6300042B2 JP2015536988A JP2015536988A JP6300042B2 JP 6300042 B2 JP6300042 B2 JP 6300042B2 JP 2015536988 A JP2015536988 A JP 2015536988A JP 2015536988 A JP2015536988 A JP 2015536988A JP 6300042 B2 JP6300042 B2 JP 6300042B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
preparation
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015536988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533175A (ja
Inventor
スリラム ナガナサン，
スリラム ナガナサン，
ネイサン グズ，
ネイサン グズ，
マシュー ファイファー，
マシュー ファイファー，
シー． グレゴリー ソウェル，
シー． グレゴリー ソウェル，
トレイシー ボスティック，
トレイシー ボスティック，
ジェイソン ヤン，
ジェイソン ヤン，
アミット スリバスタバ，
アミット スリバスタバ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2015533175A publication Critical patent/JP2015533175A/ja
Application granted granted Critical
Publication of JP6300042B2 publication Critical patent/JP6300042B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
JP2015536988A 2012-10-12 2013-10-14 癌の処置に使用するための化合物の製造方法 Active JP6300042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
US61/713,104 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017234208A Division JP2018052973A (ja) 2012-10-12 2017-12-06 癌の処置に使用するための化合物の製造方法

Publications (2)

Publication Number Publication Date
JP2015533175A JP2015533175A (ja) 2015-11-19
JP6300042B2 true JP6300042B2 (ja) 2018-03-28

Family

ID=49474740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015536988A Active JP6300042B2 (ja) 2012-10-12 2013-10-14 癌の処置に使用するための化合物の製造方法
JP2017234208A Withdrawn JP2018052973A (ja) 2012-10-12 2017-12-06 癌の処置に使用するための化合物の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017234208A Withdrawn JP2018052973A (ja) 2012-10-12 2017-12-06 癌の処置に使用するための化合物の製造方法

Country Status (31)

Country Link
US (4) US9771347B2 (enExample)
EP (1) EP2909188B1 (enExample)
JP (2) JP6300042B2 (enExample)
KR (1) KR102204520B1 (enExample)
CN (2) CN104837826B (enExample)
AU (1) AU2013328929B2 (enExample)
BR (1) BR112015008113B1 (enExample)
CA (1) CA2889466C (enExample)
CL (1) CL2015000926A1 (enExample)
CR (2) CR20200237A (enExample)
EA (1) EA030613B1 (enExample)
ES (1) ES2671502T3 (enExample)
GE (1) GEP201706690B (enExample)
HK (1) HK1213567A1 (enExample)
HR (1) HRP20180670T1 (enExample)
IL (1) IL238116B (enExample)
IN (1) IN2015DN03928A (enExample)
MA (1) MA38085B1 (enExample)
MX (2) MX372708B (enExample)
MY (1) MY186549A (enExample)
NZ (1) NZ706723A (enExample)
PE (3) PE20151494A1 (enExample)
PH (1) PH12015500785A1 (enExample)
PL (1) PL2909188T3 (enExample)
SA (1) SA515360271B1 (enExample)
SG (1) SG11201502795VA (enExample)
SI (1) SI2909188T1 (enExample)
TR (1) TR201807861T4 (enExample)
UA (1) UA115455C2 (enExample)
WO (1) WO2014059422A1 (enExample)
ZA (1) ZA201502349B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115455C2 (uk) 2012-10-12 2017-11-10 Екселіксіс, Інк. Спосіб одержання сполук для застосування при лікуванні раку
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
PL3316867T3 (pl) 2015-06-30 2021-10-11 Genentech, Inc. Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
WO2018031865A1 (en) 2016-08-12 2018-02-15 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
KR20190061030A (ko) 2016-09-29 2019-06-04 제넨테크, 인크. Mek 억제제, pd-1 축 억제제 및 탁산을 사용한 조합 요법
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
US20240173329A1 (en) 2021-03-09 2024-05-30 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
KR20230165795A (ko) 2021-04-06 2023-12-05 제넨테크, 인크. 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US6048885A (en) 1994-04-01 2000-04-11 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
KR20010014360A (ko) 1997-07-01 2001-02-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 2-(4-브로모 또는 4-요오도 페닐아미노)벤조산 유도체 및ｍｅｋ 억제제로서의 그의 용도
BR9810366A (pt) 1997-07-01 2000-08-29 Warner Lambert Co Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
CA2346684A1 (en) 1998-12-15 2000-06-22 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
EP1140291B1 (en) 1998-12-22 2005-11-23 Warner-Lambert Company Llc Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
EA200100772A1 (ru) 1999-01-13 2002-02-28 Варнер-Ламберт Компани Бензогетероциклы и их применение в качестве мек ингибиторов
EP1150950A2 (en) 1999-01-13 2001-11-07 Warner-Lambert Company Anthranilic acid derivatives
PL348870A1 (en) 1999-01-13 2002-06-17 Warner Lambert Co 1-heterocycle substituted diarylamines
BR9916885A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
KR20020012315A (ko) 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
JP2003504399A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
HK1047895A1 (zh) 1999-07-16 2003-03-14 沃尼尔‧朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
EP1202731A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
BRPI0014076B8 (pt) 1999-09-17 2021-05-25 Millennium Pharm Inc benzamidas e inibidores correlatos do fator xa
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
AP2001002217A0 (en) 2000-07-19 2001-09-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
CZ2003477A3 (cs) * 2000-08-25 2003-10-15 Warner - Lambert Company Llc Způsob přípravy N-aryl-anthranilových kyselin a jejich derivátů
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
IL160967A0 (en) 2001-10-31 2004-08-31 Pfizer Prod Inc Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
CA2473545A1 (en) 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
SI2130537T1 (sl) 2002-03-13 2013-01-31 Array Biopharma, Inc. N3-alkilirani derivati benzimidazola kot inhibitorji mek
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003238915B2 (en) 2002-06-11 2008-02-21 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US7521447B2 (en) 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
AU2004249495A1 (en) 2003-06-20 2004-12-29 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
DE602004023207D1 (de) 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
DK1682138T3 (da) 2003-11-19 2011-04-18 Array Biopharma Inc Heterocykliske inhibitorer af MEK
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
RU2361868C2 (ru) 2003-12-08 2009-07-20 Ф.Хоффманн-Ля Рош Аг Новые производные тиазола
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
CN101065358B (zh) * 2004-10-20 2015-03-11 默克雪兰诺有限公司 3-芳基氨基吡啶衍生物
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
BRPI0617165B1 (pt) * 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
EP2101759B1 (en) * 2006-12-14 2018-10-10 Exelixis, Inc. Methods of using mek inhibitors
UA115455C2 (uk) 2012-10-12 2017-11-10 Екселіксіс, Інк. Спосіб одержання сполук для застосування при лікуванні раку
BR112016017648B1 (pt) 2014-02-07 2021-01-19 Sumitomo Chemical Company, Limited método para produção de (r)-1,1,3-trimetil-4-aminoindano
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
BR112015008113A2 (pt) 2017-07-04
PH12015500785B1 (en) 2015-06-15
JP2015533175A (ja) 2015-11-19
EA201590700A1 (ru) 2015-09-30
US20170349569A1 (en) 2017-12-07
MX2015004660A (es) 2015-08-07
HK1213878A1 (en) 2016-07-15
HK1213567A1 (zh) 2016-07-08
ZA201502349B (en) 2019-12-18
BR112015008113B1 (pt) 2022-05-24
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
NZ706723A (en) 2018-07-27
US11414396B2 (en) 2022-08-16
US10239858B2 (en) 2019-03-26
EP2909188B1 (en) 2018-03-07
CR20200237A (es) 2020-07-26
IL238116B (en) 2018-06-28
SG11201502795VA (en) 2015-05-28
CA2889466A1 (en) 2014-04-17
IN2015DN03928A (enExample) 2015-10-02
JP2018052973A (ja) 2018-04-05
MX2020005533A (es) 2020-10-12
ES2671502T3 (es) 2018-06-06
SI2909188T1 (en) 2018-07-31
CN108948043A (zh) 2018-12-07
CN104837826B (zh) 2018-07-27
HRP20180670T1 (hr) 2018-07-13
UA115455C2 (uk) 2017-11-10
US9771347B2 (en) 2017-09-26
US20150210668A1 (en) 2015-07-30
PE20191818A1 (es) 2019-12-27
EA030613B1 (ru) 2018-08-31
KR102204520B1 (ko) 2021-01-20
AU2013328929B2 (en) 2018-01-04
MA38085A1 (fr) 2018-08-31
EP2909188A1 (en) 2015-08-26
CR20150245A (es) 2015-11-19
SA515360271B1 (ar) 2016-05-19
PE20151494A1 (es) 2015-11-06
MX372708B (es) 2020-05-29
TR201807861T4 (tr) 2018-06-21
CN108948043B (zh) 2021-05-04
AU2013328929A1 (en) 2015-04-30
CN104837826A (zh) 2015-08-12
US10793541B2 (en) 2020-10-06
CL2015000926A1 (es) 2015-08-28
GEP201706690B (en) 2017-06-26
WO2014059422A1 (en) 2014-04-17
PL2909188T3 (pl) 2018-08-31
US20200392104A1 (en) 2020-12-17
PH12015500785A1 (en) 2015-06-15
MY186549A (en) 2021-07-26
PE20200387A1 (es) 2020-02-24
CA2889466C (en) 2021-09-14
KR20150067339A (ko) 2015-06-17

Similar Documents

Publication Publication Date Title
JP6300042B2 (ja) 癌の処置に使用するための化合物の製造方法
CN113557235B (zh) 用于药物治疗的杂环化合物
CA2938280C (en) 4-amino-imidazoquinoline compounds
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
CN107089985B (zh) 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物
EP3126349B1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
CN103702998A (zh) 生产氮杂吲哚类的方法和中间体
TWI695831B (zh) Ｃｒｔｈ２拮抗劑化合物及其用途
WO2007058305A1 (ja) シンナミド誘導体の製造方法
AU2018208516B2 (en) Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
CA2943013A1 (en) Pyridine-2-amides useful as cb2 agonists
KR20190062081A (ko) Jak 저해제 화합물, 및 이의 제조방법
WO2022107755A1 (ja) 新規アクリジニウム塩およびその製造方法
CN111517969A (zh) 地佐辛衍生物及其医药用途
CN103328471A (zh) 制备氮杂吲唑衍生物的方法
HK1213878B (en) Novel process for making compounds for use in the treatment of cancer
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
TW201206901A (en) Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
WO2011002076A1 (ja) ラクタム化合物の製造方法およびその製造中間体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170719

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180126

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180214

R150 Certificate of patent or registration of utility model

Ref document number: 6300042

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250